TIDAL: Target-Induced Droplet Assembly of Ligands
ENERGY, DEPARTMENT OF
Place of performance: Los Alamos, NM
Don't lose track of this one
We'll email you once about this listing. No list, no cadence.
Free. Verify your email, then we send one reminder only.
- Posted
- Sep 10, 2026
- Closes
- No deadline published by the funder
Similar opportunities open now
- TECHNOLOGY LICENSING OPPORTUNITY: Bacterial Lipid Nanodiscs PlatformSame funderOpenENERGY, DEPARTMENT OFNo deadline listed
- TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterSame funderOpenENERGY, DEPARTMENT OFNo deadline listed
- TECHNOLOGY LICENSING OPPORTUNITY: Protein-Based Rare Earth Recovery via CondensationSame funderOpenENERGY, DEPARTMENT OFNo deadline listed
- TECHNOLOGY LICENSING OPPORTUNITY: SurfGraphProSame funderOpenENERGY, DEPARTMENT OFNo deadline listed
- TECHNOLOGY LICENSING OPPORTUNITY: ScreenFlow Liquid-Liquid MicrocontactorSame funderOpenENERGY, DEPARTMENT OFNo deadline listed
At a glance
This is a government contract opportunity posted by ENERGY, DEPARTMENT OF in the research and development in biotechnology (except nanobiotechnology) category. Work is performed in Los Alamos, NM.
Classification and identifiers
- Industry (NAICS)
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- Product or service (PSC)
- General Science and Technology R&D Services; General Science and Technology; Basic Research (AJ11)
- Solicitation number
- S-197478
- Contracting office
- TRIAD - DOE CONTRACTOR
Who can apply
About this opportunity
Developed by Los Alamos National Laboratory, TIDAL (Target-Induced Droplet Assembly of Ligands) transforms the small antibody fragments known as nanobodies into a programmable, protein-only material that organizes itself on demand. By harnessing a natural process called liquid-liquid phase separation, TIDAL lets these binders gather into dense, dynamic droplets precisely when they encounter their intended target, giving developers a single platform that can purify proteins without costly resins, deliver drugs as a self-forming slow-release depot and even trap harmful proteins inside living cells. The outcome is a versatile toolkit that lowers production costs, simplifies manufacturing and opens fresh therapeutic and diagnostic possibilities, all from a building block that biology already k...